PE Deals

EQT transfers stake in SHL Medical to EQT Future

SHL Medical designs, develops and manufactures drug delivery devices, such as autoinjectors, pen injectors and advanced inhaler systems.

-
  • EQT first partnered with SHL Medical in January 2020 through its EQT VIII fund
  • The new consortium of investors include single family office ATHOS
  • Roger Samuelsson, SHL Medical’s founder, will remain the majority shareholder

EQT Future, and ATHOS, alongside other co-investors, announced an investment in SHL Medical. The consortium will acquire a minority share of the company from EQT’s equity fund VIII. Roger Samuelsson, SHL Medical’s founder, will remain the majority shareholder.

Headquartered in Zug, Switzerland, SHL Medical designs, develops and manufactures drug delivery devices, such as autoinjectors, pen injectors and advanced inhaler systems, and provides final assembly, labelling, and packaging services for pharma and biotech companies worldwide. The company has locations in Taiwan, Sweden and the US.

Since EQT VIII’s investment in 2020, SHL Medical has “significantly” outperformed its business plan, according to EQT, having upgraded its manufacturing and commercial capabilities while focusing on digitalisation. SHL Medical is working on new product launches while expanding its production to the US and Europe.

“EQT Future backs market-leading businesses which improve our planet through the products and services they deliver, while having the potential to shape their industries,” said Rikke Kjær Nielsen, partner within EQT Future’s advisory team. “SHL Medical is all of this and more.”

Stockholm-based EQT is a global investment organisation founded in 1994.